<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34106031</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8336</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Expert review of anti-infective therapy</Title>
          <ISOAbbreviation>Expert Rev Anti Infect Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.</ArticleTitle>
        <Pagination>
          <StartPage>3</StartPage>
          <EndPage>15</EndPage>
          <MedlinePgn>3-15</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14787210.2021.1939011</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Onychomycosis, a common nail disorder caused by fungal infection, can be managed pharmaceutically with oral or topical treatments. While oral treatments are often used first-line to treat nail infections, these systemic antifungals are not appropriate for all patients, and no oral treatments are approved for use in children in the USA. Given this need, topical antifungals were developed, which can be used as monotherapy or in combination with oral drugs.</AbstractText>
          <AbstractText Label="AREAS COVERED" NlmCategory="METHODS">Efinaconazole 10% solution is an azole antifungal indicated for topical treatment of toenail onychomycosis in pediatric and adult patients. This qualitative literature review summarizes available chemical, pharmacological, efficacy, safety, and post-marketing surveillance data of efinaconazole 10% topical solution. Efinaconazole 10% has been shown to be safe and efficacious regardless of disease severity/duration at baseline; patient gender, ethnicity, or age (including pediatrics); or comorbidities such as diabetes or tinea pedis. Overall, efinaconazole is a safe and effective clinical option for the treatment and management of onychomycosis.</AbstractText>
          <AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Efinaconazole is the first new antifungal approved for onychomycosis in 10Â years in the USA. It has comparable efficacy to systemic antifungal agents such as itraconazole, and a favorable adverse events profile with minimal systemic exposure and no drug-drug interactions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vlahovic</LastName>
            <ForeName>Tracey C</ForeName>
            <Initials>TC</Initials>
            <AffiliationInfo>
              <Affiliation>Temple University School of Podiatric Medicine, Philadelphia, PA, US.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Aditya K</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>Mediprobe Research Inc., London, ON, CAN.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Toronto, Toronto, ON, CAN.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Rev Anti Infect Ther</MedlineTA>
        <NlmUniqueID>101181284</NlmUniqueID>
        <ISSNLinking>1478-7210</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J82SB7FXWB</RegistryNumber>
          <NameOfSubstance UI="C431707">efinaconazole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014009" MajorTopicYN="Y">Onychomycosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010372" MajorTopicYN="Y">Pediatrics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">IDP-108</Keyword>
        <Keyword MajorTopicYN="Y">KP-103</Keyword>
        <Keyword MajorTopicYN="Y">antifungal</Keyword>
        <Keyword MajorTopicYN="Y">azole</Keyword>
        <Keyword MajorTopicYN="Y">efinaconazole</Keyword>
        <Keyword MajorTopicYN="Y">lacquer</Keyword>
        <Keyword MajorTopicYN="Y">onychomycosis</Keyword>
        <Keyword MajorTopicYN="Y">pediatric</Keyword>
        <Keyword MajorTopicYN="Y">topical</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34106031</ArticleId>
        <ArticleId IdType="doi">10.1080/14787210.2021.1939011</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
